HAFNARFJORDUR, ICELAND--(Marketwire - August 19, 2008) - Reykjavik, Iceland, 19 August 2008 - - Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately.
